{"filing":{"accession_number":"0001493152-26-043659","cik":"0001799011","ticker":"LUCD","company_name":"Lucid Diagnostics Inc.","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1799011/000149315226043659/form8-k.htm"},"events":[{"id":34219,"run_id":31488,"accession_number":"0001493152-26-043659","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces favorable regulatory and coding outcomes for Lucid's EsoGuard and EsoCheck products: CMS Medicare Advisory Panel recommended maintaining the original gapfill payment basis, AMA CPT Editorial Panel approved a new Category III CPT code for non-endoscopic cell collection, and CDC/NCHS ICD-10 Coordination Committee favorably received a proposal for a new diagnosis code. These advances directly expand reimbursement and billing pathways for the company's commercial-stage diagnostic products, representing material operational and commercial progress that would affect investor assessment of the company's market access and revenue potential.","company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":37898,"accession_number":"0001493152-26-043659","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces favorable regulatory and coding outcomes for Lucid's EsoGuard and EsoCheck products: CMS Medicare Advisory Panel recommended maintaining the original gapfill payment basis, AMA CPT Editorial Panel approved a new Category III CPT code for non-endoscopic cell collection, and CDC/NCHS ICD-10 Coordination Committee favorably received a proposal for a new diagnosis code. These advances directly expand reimbursement and billing pathways for the company's commercial-stage diagnostic products, representing material operational and commercial progress that would affect investor assessment of the company's market access and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T13:07:42.410277+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37898,"accession_number":"0001493152-26-043659","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces favorable regulatory and coding outcomes for Lucid's EsoGuard and EsoCheck products: CMS Medicare Advisory Panel recommended maintaining the original gapfill payment basis, AMA CPT Editorial Panel approved a new Category III CPT code for non-endoscopic cell collection, and CDC/NCHS ICD-10 Coordination Committee favorably received a proposal for a new diagnosis code. These advances directly expand reimbursement and billing pathways for the company's commercial-stage diagnostic products, representing material operational and commercial progress that would affect investor assessment of the company's market access and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T13:07:42.410277+00:00","company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","filing_date":"2026-09-22"}]}